Viral Therapy of Cancer

Description

In the last decade there has been an explosion of interest in viral therapies for cancer. Viral agents have been developed that are harmless to normal tissues but selectively able to kill cancer cells. These agents have been endowed with additional selectivity and potency through genetic manipulation. Increasingly these viruses are undergoing evaluation in clinical trials, both as single agents and in combination with standard chemotherapy and radiotherapy.  This book provides a comprehensive yet succinct overview of the current status of viral therapy of cancer. Chapters coherently present the advances made with individual agents and review the biological and clinical background to a range of viral therapies: structured to proceed from basic science at the bench to the patient’s bedside, they give an up-to-date and realistic evaluation of a therapy’s potential utility for the cancer patient. Presents state of the art knowledge on how viruses can be, and have been, used in novel therapeutic approaches for the treatment of cancer Describes the use of viruses as oncolytic agents, killing cells directly Editors are experts in the field, with experience of both laboratory and clinical research Viral Therapy of Cancer is essential reading for both basic scientists and clinicians with an interest in viral therapy and gene therapy.Content: Chapter 1 Adenoviruses (pages 1–17): Kate Relph, Kevin J. Harrington, Alan Melcher and Hardev S. PandhaChapter 2 Application of HSV?1 Vectors to the Treatment of Cancer (pages 19–53): Paola Grandi, Kiflai Bein, Costas G. Hadjipanayis, Darren Wolfe, Xandra O. Breakefield and Joseph C. GloriosoChapter 3 Adeno?Associated Virus (pages 55–68): Selvarangan PonnazhaganChapter 4 Retroviruses (pages 69–81): Simon Chowdhury and Yasuhiro IkedaChapter 5 Lentiviral Vectors for Cancer Gene Therapy (pages 83–94): Antonia Follenzi and Elisa VignaChapter 6 Poxviruses as Immunomodulatory Cancer Therapeutics (pages 95–114): Kevin J. Harrington, Hardev S. Pandha and Richard G. VileChapter 7 Oncolytic Herpes Simplex Viruses (pages 115–137): Guy R. Simpson and Robert S. CoffinChapter 8 Selective Tumour Cell Cytotoxicity by Reoviridae – Preclinical Evidence and Clinical Trial Results (pages 139–150): Laura Vidal, Matt Coffey and Johann de BonoChapter 9 Oncolytic Vaccinia (pages 151–169): M. Firdos Ziauddin and David L. BartlettChapter 10 Newcastle Disease Virus: A Promising Vector for Viral Therapy of Cancer (pages 171–186): Volker Schirrmacher and Philippe FournierChapter 11 Vesicular Stomatitis Virus (pages 187–203): John Bell, Kelly Parato and Harold AtkinsChapter 12 Measles as an Oncolytic Virus (pages 205–215): Adele FieldingChapter 13 Alphaviruses (pages 217–228): Ryuya YamanakaChapter 14 Tumour?Suppressor Gene Therapy (pages 229–239): Bingliang Fang and Jack A. RothChapter 15 RNA Interference and Dominant Negative Approaches (pages 241–254): Charlotte Moss and Nick LemoineChapter 16 Gene?Directed Enzyme Prodrug Therapy (pages 255–276): Silke Schepelmann, Douglas Hedley, Lesley M. Ogilvie and Caroline J. SpringerChapter 17 Immunomodulatory Gene Therapy (pages 277–294): Denise Boulanger and Andrew BatemanChapter 18 Antiangiogenic Gene Delivery (pages 295–312): Anita T. Tandle and Steven K. LibuttiChapter 19 Radiosensitization in Viral Gene Therapy (pages 313–326): Jula Veerapong, Kai A. Bickenbach and Ralph R. WeichselbaumChapter 20 Radioisotope Delivery (pages 327–340): Inge D. L. Peerlinck and Georges VassauxChapter 21 Radioprotective Gene Therapy: Current Status and Future Goals (pages 341–375): Joel S. Greenberger and Michael W. EpperlyChapter 22 Chemoprotective Gene Delivery (pages 377–391): Michael Milsom, Axel Schambach, David Williams and Christopher Baum